Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

The Prognostic Value of YKL-40 in Allogeneic Hematopoietic Cell Transplantation

Brian Kornblit, MD PhD, Tao Wang, PhD, Stephanie J. Lee, MD MPH, Stephen R. Spellman, MBS, Xiaochun Zhu, MS, Katharina Fleischhauer, MD, Carlheinz Müller, MD PhD, Michael R. Verneris, MD, Julia S. Johansen, MD DMSci, Lars Vindelov, MD DMSci, Peter Garred, MD DMSci

Blood (2014) 124 (21): 1176.

https://doi.org/10.1182/blood.V124.21.1176.1176

Published: 2014

Journal Articles

Impact of Postremission Consolidation Chemotherapy On Outcome After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for AML in First Complete Remission (CR1): A Report From the Acute Leukemia Working Party of EBMT.

Moshe Yeshurun, MD, Myriam Labopin, Didier Blaise, MD, Jan Cornelissen, MD PhD, Henrik Sengeloev, MD, PhD, Lars Vindelov, MD, Jurgen H Kuball, MD, PhD, Patrice Chevallier, MD, PhD, Arnon Nagler, MD, Mohamad Mohty, MD PhD

Blood (2012) 120 (21): 3098.

https://doi.org/10.1182/blood.V120.21.3098.3098

Published: 2012

Journal Articles

Equivalent Outcome Between Older Siblings and Unrelated Donors After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients Older Than 50 Years with Acute Myeloid Leukemia in First Complete Remission: A Report From the ALWP of EBMT

Regis Peffault de Latour, Myriam Labopin, Jan Cornelissen, MD PhD, Lars Vindelov, MD, Didier Blaise, MD, Noel Milpied, MD, Anne Huyn, MD, Charles F. Craddock, BM, MRCP, MRCPath, Nigel Russel, Vladimir Koza, MD, Bruno Lioure, MD, Richard Schouten, BSc, Dolores Caballero, MD, Jean-Yves Cahn, MD, Nathalie Fegueux, MD, Mohamad Mohty, MD PhD

Blood (2012) 120 (21): 961.

https://doi.org/10.1182/blood.V120.21.961.961

Published: 2012

Journal Articles

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era

Blood (2012) 119 (17): 4083–4090.

https://doi.org/10.1182/blood-2012-02-409763

Published: 2012

Journal Articles

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

Blood (2012) 119 (6): 1599–1606.

https://doi.org/10.1182/blood-2011-08-375840

Published: 2012

Includes: Supplemental data

Journal Articles

Impact of Chronic Graft-Versus-Host disease (GVHD) After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) As Treatment for Acute Myeloid Leukemia (AML): A Survey From the Acute Leukemia Working Party of the EBMT

Frederic Baron, MD, PhD, Myriam Labopin, MD, MS, Dietger Niederwieser, MD, noel-Jean Milpied, MD, Jan J Cornelissen, MD PhD, Claes Malm, MD, Lars Vindelov, MD, Didier Blaise, MD, Jeroen JWM Janssen, MD, Eefke J Petersen, MD PhD, Gerard Socie, Vanderson Rocha, MD, PhD, Arnon Nagler, Mohamad Mohty

Blood (2011) 118 (21): 321.

https://doi.org/10.1182/blood.V118.21.321.321

Published: 2011

Journal Articles

Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

Mohamed L. Sorror, MD, MSc, Barry Storer, PhD, Brenda M. Sandmaier, MD, Leanthe Braunert, MD, Ginna G. Laport, MD, Thomas Chauncey, MD, Christopher Bredeson, Richard T Maziarz, MD, Michael A. Pulsipher, MD, Edward Agura, MD, Michael T. Maris, MD, Lars Vindelov, MD, Firoozeh Sahebi, M.D., Peter McSweeney, Benedetto Bruno, MD, Amelia Langston, MD, Rainer F. Storb, MD, David G. Maloney

Blood (2010) 116 (21): 2364.

https://doi.org/10.1182/blood.V116.21.2364.2364

Published: 2010

Journal Articles

A Randomized 3-Arm Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial.

Brenda M. Sandmaier, MD, Michael Maris, MD, Barry Storer, PhD, Lars Vindelov, MD, Amelia Langston, MD, James C. Wade, MD, MPH, Wolfgang A. Bethge, MD, Michael Pulsipher, MD, Thoralf Lange, MD, Thomas Chauncey, MD, Finn Petersen, MD, Kai Hübel, MD, Ann Woolfrey, MD, Mary E.D. Flowers, MD, David G. Maloney, MD, PhD, Rainer F. Storb, MD

Blood (2009) 114 (22): 348.

https://doi.org/10.1182/blood.V114.22.348.348

Published: 2009

Journal Articles

Association of HMGB1 Polymorphisms with Outcome After Allogeneic Hematopoietic Cell Transplantation.

Brian Kornblit, MD, Tania Nicole Masmas, MD, Søren Lykke Petersen, Hans O Madsen, Carsten Heilmann, Lone Schejbel, Henrik Sengeloev, Klaus Müller, Peter Garred, Lars Vindelov, MD

Blood (2009) 114 (22): 2260.

https://doi.org/10.1182/blood.V114.22.2260.2260

Published: 2009

Journal Articles

Genetic Variation in AKAP13 Is Associated with Increased Risk of Relapse after Allogeneic Hematopoietic Cell Transplantation Following Non-Myeloablative Conditioning.

Brian Kornblit, MD, Tania Masmas, Hans O Madsen, Mette V Larsen, Anette Stryhn, Søren Buus, Peter Garred, Lars Vindelov

Blood (2008) 112 (11): 3257.

https://doi.org/10.1182/blood.V112.11.3257.3257

Published: 2008

Journal Articles

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia

Blood (2008) 112 (11): 149.

https://doi.org/10.1182/blood.V112.11.149.149

Published: 2008

Journal Articles

The Predictive Value of Gene Expression Profiles for Acute Graft-Versus-Host Disease after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning for Hematological Malignancy.

Tania N. Masmas, MD, Lennart Friis-Hansen, M.D., Jens Vilstrup Johansen, M.S., Soren Lykke Petersen, M.D., Brian T. Kornblit, M.D., Ole Winther, M.S., Finn Cilius Nielsen, M.D., Lars Vindelov, M.D.

Blood (2007) 110 (11): 1079.

https://doi.org/10.1182/blood.V110.11.1079.1079

Published: 2007

Journal Articles

The PTPN22 1858C/T Polymorphism Is Associated with the Development of Grade 3 to 4 Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation Following Nonmyeloablative Conditioning.

Brian Kornblit, MD, Tania Masmas, MD, Soren L. Petersen, MD, Hans O. Madsen, MSc, Peter Garred, MD, Lars Vindelov, MD

Blood (2007) 110 (11): 1969.

https://doi.org/10.1182/blood.V110.11.1969.1969

Published: 2007

Journal Articles

Kinetics of Early Donor Chimerism after Nonmyeloablative Haematopoietic Stem Cell Transplantation Monitored with High-Resolution Real Time Quantitative PCR.

Tania N. Masmas, MD, Soren L. Petersen, MD, Hans O. Madsen, MS, Lars Ryder, MS, Ebbe Dickmeiss, MD, D.Msc., Arne Svejgaard, MD, D.Msc., Lars Vindelov, MD, D.Msc.

Blood (2005) 106 (11): 3669.

https://doi.org/10.1182/blood.V106.11.3669.3669

Published: 2005

Journal Articles

Evidence for Involvement of Clonally Expanded CD8 + T Cells in Anti-Cancer Immune Responses in CLL Patients Following Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT).

Tania Kollgaard, MSc, Soren L. Petersen, M.D, Sine Reker Hadrup, Ph.D, Tania N. Masmas, M.D, Tina Seremet, M.Sc., Mads H. Andersen, Ph.D, Hans O. Madsen, Ph.D, Lars Vindelov, M.D, Per Thor Straten, Ph.D

Blood (2005) 106 (11): 1260.

https://doi.org/10.1182/blood.V106.11.1260.1260

Published: 2005

Journal Articles

Cytokine Gene Expression in Peripheral Blood Mononuclear Cells Points to Interleukin-10 as an Inhibitor of Alloreactivity Following Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning.

Soren L. Petersen, MD, Hans O. Madsen, M.Sc, Lars P. Ryder, M.Sc, Arne Svejgaard, MD, D. Msc, Ebbe Dickmeiss, MD, D. Msc, Lars Vindelov, MD, D.Msc.

Blood (2005) 106 (11): 5342.

https://doi.org/10.1182/blood.V106.11.5342.5342

Published: 2005

NARROW

The Prognostic Value of YKL-40 in Allogeneic Hematopoietic Cell Transplantation

Impact of Postremission Consolidation Chemotherapy On Outcome After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for AML in First Complete Remission (CR1): A Report From the Acute Leukemia Working Party of EBMT.

Equivalent Outcome Between Older Siblings and Unrelated Donors After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients Older Than 50 Years with Acute Myeloid Leukemia in First Complete Remission: A Report From the ALWP of EBMT

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

Impact of Chronic Graft-Versus-Host disease (GVHD) After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) As Treatment for Acute Myeloid Leukemia (AML): A Survey From the Acute Leukemia Working Party of the EBMT

Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

Association of HMGB1 Polymorphisms with Outcome After Allogeneic Hematopoietic Cell Transplantation.

Genetic Variation in AKAP13 Is Associated with Increased Risk of Relapse after Allogeneic Hematopoietic Cell Transplantation Following Non-Myeloablative Conditioning.

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia

The Predictive Value of Gene Expression Profiles for Acute Graft-Versus-Host Disease after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning for Hematological Malignancy.

The PTPN22 1858C/T Polymorphism Is Associated with the Development of Grade 3 to 4 Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation Following Nonmyeloablative Conditioning.

Kinetics of Early Donor Chimerism after Nonmyeloablative Haematopoietic Stem Cell Transplantation Monitored with High-Resolution Real Time Quantitative PCR.

Evidence for Involvement of Clonally Expanded CD8 + T Cells in Anti-Cancer Immune Responses in CLL Patients Following Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT).

Cytokine Gene Expression in Peripheral Blood Mononuclear Cells Points to Interleukin-10 as an Inhibitor of Alloreactivity Following Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only